SavedAdd your journal

Journals / CURRENT THORACIC SURGERY / 2016 / Cilt: 1 Sayı: 1

Effect of tumor size on survival in pN0M0 non-small cell lung cancer patients

Gökhan Kocaman
Cabir Yüksel
Bülent Mustafa Yenigün
Mehmet Ali Sakallı
Durdu Karasoy
Murat Özkan
Serkan Enön
Ayten Kayı Cangır
Pages
12–15
Publication Date
2016-12-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to evaluate the prognostic effect of tumor size on overall survival and to determine a cut-off point for tumor size.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Tumor size is one of the major prognostic determinants of non-small cell lung cancer (NSCLC).
📊
Key Findings & Data:In the present study, we evaluated the effect of tumor size on survival in pN0M0 NSCLC patients.
💡
Conclusion & Impact:We aimed to evaluate the prognostic effect of tumor size on overall survival and to determine a cut-off point for tumor size.
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Non-small cell lung cancer · tumor size · survival

Abstract

Background: Tumor size is one of the major prognostic determinants of non-small cell lung cancer (NSCLC). In the present study, we evaluated the effect of tumor size on survival in pN0M0 NSCLC patients. Materials and Methods: Between 1994 and 2013, 1975 NSCLC patients underwent surgery in our center. The study included 774 NSCLC patients with pathological stage N0M0, and these patients were divided into 8 groups according to tumor diameter, as follows, Group 1: 0-10 mm, Group 2: 11-20 mm, Group 3: 21-30 mm, Group 4: 31-40 mm, Group 5: 41-50 mm, Group 6: 51-60 mm, Group 7: 61-70 mm, and Group 8: > 70 mm. We aimed to evaluate the prognostic effect of tumor size on overall survival and to determine a cut-off point for tumor size. Results: The 5 year overall survival rate for groups 1 to 8 were 85.6%, 81.3%, 68.6%, 62.2%, 55%, 54.2%, 54.3%, and 45.6%, respectively. The mean follow-up time was 43.8 months. In multivariate analysis, age, tumor size, and surgical resection type had an independent prognostic value on survival. Conclusions : Tumor size is an independent prognostic factor for pN0M0 NSCLC patients. A tumor size of 4 cm was found to be the most suitable cut-off point for survival which may be of help in decision-making for adjuvant chemotherapy.

🔖

Cite This Article

Kocaman, G., Yüksel, C., Yenigün, B. M., Sakallı, M. A., Karasoy, D., Özkan, M., Enön, S., Cangır, A. K. (2016). Effect of tumor size on survival in pN0M0 non-small cell lung cancer patients. CURRENT THORACIC SURGERY, Cilt: 1 Sayı: 1, 12–15. https://ajindex.com/articles/984624

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. IASLC Staging and Prognos¬tic Factors Committee, Advisory Boards and Participating Institutions. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 2015; 10:990-1003.
  2. Zhang J, Gold AK, Lin HY, Swisher SG, Xing Y, Lee JJ, et al. Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol 2015; 10:682-90.
  3. Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study. J Thorac Cardiovasc Surg 2006; 132:769-75.
  4. Sihoe ADL, Van Schil P. Non-small cell lung cancer: When to offer sublobar resection. Lung Cancer 2016; 84:115-20.
  5. Takeda S-i, Fukai S, Komatsu H, Nemoto E, Nakamura K, Murakami M. Impact of large tumor size on survival after resection of pathologically node negative (pN0) non-small cell lung cancer. Ann Thorac Surg 2005; 79:1142-6.
  6. Cangır AK, Kutlay H, Akal M, Güngör A, Özdemir N, Akay H. Prognostic value of tumor size in non-small cell lung cancer larger than five centimeters in diameter. Lung Cancer 2004; 26:325-31.
  7. Zhang Y, Sun Y, Chen H. Effect of tumor size on prognosis of node-negative lung cancer with sufficent lymph node examination and no disease extension. Onco Targets and Therapy 2016; 9:649-53.
  8. Speicher PJ, Gu L, Wang X, Hartwig MG, D’Amico TA, Berry MF. Adjuvant chemotherapy after lobectomy for T1-2N0 non-small cell lung cancer: are the guidelines supported? J Natl Compr Canc Netw 2015; 13:755-61.
  9. Malhotra J, Mhango G, Gomez JE, Smith C, Galsky MD, Strauss GM, et al. Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis. Ann Oncol 2015; 26:768-73.
  10. Strauss GM, Herndon II JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non–small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26:5043-51.